Advancing Size Exclusion Chromatography (SEC) for Characterization of Genetic Therapeutics
The rapid growth of genetic medicines - including oligonucleotides, plasmid DNA, mRNA, lipid nanoparticles (LNPs), and viral vectors - has introduced unprecedented analytical challenges. From shear‑induced degradation to poor resolution and reproducibility, traditional SEC approaches often struggle to deliver actionable insights for development, scale‑up, and QC.
In this webinar, we explore next‑generation SEC columns designed specifically for mega molecules. Discover how wide‑pore SEC technology enables robust, high‑resolution size‑based characterization while preserving sample integrity. Through real‑world examples and best practices, our speaker will demonstrate how modern SEC workflows support faster decision‑making, improved inter‑lab reproducibility, and smoother regulatory pathways for advanced genetic medicine products.
What You’ll Learn
Attendees will gain practical insights into:
- Common SEC challenges in analyzing plasmids, mRNA, LNPs, and viral vectors
- Strategies to minimize shear degradation and maintain biomolecule integrity during separation
- Optimizing SEC methods for mega molecules using wide‑pore column technology
- How to achieve reproducible, high‑resolution separations across labs and sites
- Best practices for method development and extending SEC column lifetime
- How faster SEC workflows can reduce development timelines and support regulatory submissions
Why attend?
Traditional sizing techniques often fall short when applied to today’s complex, high‑molecular‑weight genetic medicines, leading to low resolution, high variability, and long run times.
In this session, you’ll learn how modern wide‑pore SEC solutions:
- Deliver robust, high‑throughput profiling for early discovery through late‑stage development
- Support multi‑attribute characterization, including size distribution, aggregates, and integrity
- Enable seamless integration with MALS detection for enhanced molecular weight and structural insight
Who should attend?
This webinar is ideal for analytical scientists, process development teams, QC laboratories, and CROs working in cell and gene therapy, vaccines, and RNA‑based therapeutics.
Presenter: Ali Tiss, Ph.D., MSc., Eng. (Chemistry Market Development Manager, Biopharma & Cell and Gene Therapies, Waters Corporation)
Ali joined Waters in 2021 and has since supported colleagues and users in the biomolecule separation field (proteins, peptides, Abs, conjugates, Cell & Gene Therapy products). Ali completed his Ph.D. in biochemistry and structural biology at the Mediterranean University (CNRS, Marseille, France), where he contributed to the R&D of the anti-obesity drug, Xenical®, developed by Roche Ltd. Then, he earned over two decades of research experience in biochemistry, liquid chromatography, mass spectrometry, and proteomics, focusing on detecting and characterizing biomarkers related to human diseases such as cancer, diabetes, and obesity. Ali is passionate about supporting customer business and innovative applications.
